Multimodal investigations of trans-endothelial cell trafficking under condition of disrupted blood-brain barrier integrity

BMC Neuroscience

Volumn 11, Issue , 2010, Pages

  Marchi, Nicola ^a   Teng, Qingshan ^a   Nguyen, Minh T ^a   Franic, Linda ^a   Desai, Nirav K ^a   Masaryk, Thomas ^a   Rasmussen, Peter ^a   Trasciatti, Silvia ^b   Janigro, Damir ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b Abiogen Pharma SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN TUMOR; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SPINAL CORD TUMOR; SWINE; ANIMAL; BLOOD FLOW VELOCITY; BRAIN; BRAIN CIRCULATION; CAPILLARY PERMEABILITY; CAROTID ARTERY; CELL MOTION; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; PHYSIOLOGY; TIME; TRANSPLANTATION; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD FLOW VELOCITY; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CAROTID ARTERIES; CELL LINE, TUMOR; CELL MOVEMENT; CEREBROVASCULAR CIRCULATION; ENDOTHELIUM, VASCULAR; HUMANS; MAGNETIC RESONANCE IMAGING; SWINE; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 77951191762     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-11-34     Document Type: Article

References (28)

1. Abbott NJ, Revest PA, Romero IA. Astrocyte-endothelial interaction: physiology and pathology. Neuropathology-And-Applied-Neurobiology 1992, 18:424-433. 10.1111/j.1365-2990.1992.tb00808.x, 1454132.
2. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007, 12:54-61. 10.1016/j.drudis.2006.10.013, 17198973.
3. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201. 10.1016/j.neuron.2008.01.003, 18215617.
4. Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)?. Trends Immunol 2007, 28:5-11. 10.1016/j.it.2006.11.007, 17140851.
5. Galea I, Bechmann I, Perry VH. What is immune privilege (not)?. Trends Immunol 2007, 28:12-18. 10.1016/j.it.2006.11.004, 17129764.
6. Grant GA, Janigro D. The blood-brain barrier. Youmans Neurological Surgery 2004, 1:153-174. Philadelphia, PA: Saunders, Winn HR.
7. Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom DM, Stevens G, McGregor J, Jahnke K, Lacy CA, Hedrick NA, Shalom E, Ference S, Bell S, Sorenson L, Tyson RM, Haluska M, Neuwelt EA. Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience. Journal of Clinical Oncology 2009, 27:3503-3509. 10.1200/JCO.2008.19.3789, 19451444.
8. Kajiwara K, Ito H, Fukumoto T. Lymphocyte Infiltration Into Normal Rat-Brain Following Hyperosmotic Blood-Brain-Barrier Opening. J Neuroimmunol 1990, 27:133-140. 10.1016/0165-5728(90)90062-R, 2110183.
9. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998, 42:1083-1099. 10.1097/00006123-199805000-00082, 9588554.
10. Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, Hernandez N, Hallene K, Diglaw T, Franic L, Najm I, Janigro D. Seizure-Promoting Effect of Blood-Brain Barrier Disruption. Epilepsia 2007, 48(4):732-742. 10.1111/j.1528-1167.2007.00988.x, 17319915.
11. Elkassabany NM, Bhatia J, Deogaonkar A, Barnett GH, Lotto M, Maurtua M, Ebrahim Z, Schubert A, Ference S, Farag E. Perioperative complications of blood brain barrier disruption under general anesthesia: a retrospective review. J Neurosurg Anesthesiol 2008, 20:45-48. 10.1097/ANA.0b013e31815d5f1f, 18157025.
12. Cesano A, Visonneau S, Pasquini S, Rovera G, Santoli D. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res 1996, 56:4444-4452.
13. Kruse CA, Visonneau S, Kleinschmidt-DeMasters BK, Gup CJ, Gomez GG, Paul DB, Santoli D. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: Implications for local adoptive immunotherapy. Cancer Res 2000, 60:5731-5739.
14. Cesano A, Visonneau S, Cioe L, Clark SC, Santoli D. Effects of Lethal Irradiation and Cyclosporine-A Treatment on the Growth and Tumoricidal Activity of A T-Cell Clone Potentially Useful in Cancer-Therapy. Cancer Immunology Immunotherapy 1995, 40:139-151.
15. Lamb C, Vissoneau S, Gup C, Gomez G, DeMasters BK, Santoli D, Kruse CA. TALL-104 cell killing of human malignant brain tumors by necrotic/apoptotic events and the trafficking of TALL-104 cells through tumor-bearing rat brain. FASEB J 1999, 13:A302.
16. Fieschi C, Lenzi GL, Zanette E, Orzi F, Passero S. Effects on EEG of the osmotic opening of the blood-brain barrier in rats. Life Sci 1980, 27:239-243. 10.1016/0024-3205(80)90143-5, 6772908.
17. Geoerger B, Tang CB, Cesano A, Visonneau S, Marwaha S, Judy KD, Sutton LN, Santoli D, Phillips PC. Activity of the MHC-nonrestricted T-cell line TALL-104 in the treatment of Central Nervous System tumor xenografts. Clinical Cancer Research 1999, 5:3760S.
18. Geoerger B, Tang CB, Cesano A, Visonneau S, Marwaha S, Judy KD, Sutton LN, Santoli D, Phillips PC. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts. Neuro-Oncology 2000, 2:103-113. 10.1215/15228517-2-2-103, 1919516, 11303619.
19. Visonneau S, Cesano A, Tran T, Jeglum KA, Santoli D. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104. Clinical Cancer Research 1997, 3:1789-1797.
20. Visonneau S, Cesano A, Jeglum KA, Santoli D. Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104. Oncology Reports 1999, 6:1181-1188.
21. Visonneau S, Cesano A, Jeglum KA, Santoli D. Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104. Clinical Cancer Research 1999, 5:1868-1875.
22. Visonneau S, Cesano A, Porter DL, Luger SL, Schuchter L, Kamoun M, Torosian MH, Duffy K, Sickles C, Stadtmauer EA, Santoli D. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clinical Cancer Research 2000, 6:1744-1754.
23. Marchi N, Batra A, Fan Q, Carlton E, Caponi C, Najm I, Granata T, Janigro D. Antagonism of peripheral inflammation prevents status epilepticus. Neurobiol Dis 2009, 33:171-271. 10.1016/j.nbd.2008.10.002, 19010416.
24. Marchi N, Betto G, Fazio V, Fan Q, Ghosh C, Machado A, Janigro D. Blood-Brain Barrier Damage and Brain Penetration of Antiepileptic Drugs: Role of Serum Proteins and Brain Edema. Epilepsia 2009, 50:664-677. 10.1111/j.1528-1167.2008.01989.x, 2824251, 19175391.
25. Fabene PF, Navarro MG, Martinello M, Rossi B, Merigo F, Ottoboni L, Bach S, Angiari S, Benati D, Chakir A, Zanetti L, Schio F, Osculati A, Marzola P, Nicolato E, Homeister JW, Xia L, Lowe JB, McEver RP, Osculati F, Sbarbati A, Butcher EC, Constantin G. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med 2008, 14:1377-1383. 10.1038/nm.1878, 2710311, 19029985.
26. Cornford EM, Hyman S, Swartz BE. The human brain GLUT1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia. J Cereb Blood Flow Metab 1994, 14:106-112.
27. Cornford EM, Hyman S. Blood-brain barrier permeability to small and large molecules. Advanced Drug Delivery Reviews 1999, 36:145-163. 10.1016/S0169-409X(98)00082-9, 10837713.
28. Visonneau S, Cesano A, Torosian MH, Santoli D. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice. Clinical Cancer Research 1997, 3:1491-1500.